Last updated: February 19, 2026
Patent CN102905706, titled "Anticancer activity of a compound, preparation and use," filed by the Chinese Academy of Sciences, claims a novel chemical compound and its application in cancer treatment. The patent covers a specific molecular entity, denoted as compound X, and its pharmaceutical compositions. The claims are structured to encompass the compound itself, methods of its preparation, and therapeutic uses in treating various cancers. Analysis of the patent landscape reveals potential for market exclusivity and licensing opportunities for this compound and its derivatives.
What is the Core Invention of CN102905706?
The central innovation of patent CN102905706 is the identification and characterization of compound X, a small molecule demonstrating potent anticancer activity. The patent details the chemical structure of compound X and its synthesis. Crucially, it also provides preclinical data supporting its efficacy against a range of cancer cell lines.
- Chemical Structure: The patent discloses the specific chemical formula and structural representation of compound X. This structural specificity is a cornerstone of patent protection, defining the exact molecular entity claimed.
- Preparation Method: CN102905706 outlines a detailed synthetic route for producing compound X. This includes specific reagents, reaction conditions, and purification steps. The reproducibility and efficiency of this method are critical for commercial viability.
- Anticancer Activity: The patent asserts that compound X possesses significant anticancer properties. This is supported by in vitro data presented in the patent, demonstrating inhibition of cancer cell proliferation and induction of apoptosis in various cancer types.
- Pharmaceutical Compositions: The invention extends to pharmaceutical formulations containing compound X as an active ingredient. These compositions are designed for administration to patients, implying development towards a drug product.
What are the Key Claims in CN102905706?
The claims within CN102905706 define the legal boundaries of the patented invention. They are typically divided into independent claims (broadest scope) and dependent claims (narrower scope, referring back to independent claims).
Independent Claims:
- Compound X: This claim directly protects the specific chemical structure of compound X. Any unauthorized synthesis, use, or sale of this exact compound falls under infringement.
- Pharmaceutical Composition: This claim covers formulations containing compound X along with pharmaceutically acceptable carriers, diluents, or excipients. This broadens protection beyond the active ingredient to its deliverable forms.
- Method of Preparation: This claim protects the specific process described in the patent for synthesizing compound X. Competitors cannot use this exact method without license.
- Method of Treatment: This claim protects the use of compound X for treating specific types of cancer. This is a method-of-use claim, which is crucial for therapeutic applications.
Dependent Claims:
Dependent claims further refine and limit the scope of the independent claims, often by adding specific characteristics or variations. Examples might include:
- Claims specifying particular salt forms, solvates, or polymorphs of compound X.
- Claims detailing specific types of pharmaceutical compositions (e.g., oral tablets, injectable solutions).
- Claims specifying particular cancer types (e.g., lung cancer, breast cancer, colorectal cancer) for the method of treatment.
The precise wording of each claim is paramount. The scope of protection is determined by the language used, and any ambiguity can lead to challenges during enforcement.
What is the Scope of Compound X and its Derivatives?
The patent's scope for compound X is defined by its specific chemical structure. However, a comprehensive analysis requires consideration of potential derivatives and related compounds that might be developed.
- Structural Variants: While the patent explicitly claims compound X, innovation often involves creating structurally similar molecules (analogs) with potentially improved properties (e.g., efficacy, pharmacokinetics, reduced toxicity). The patent may include broader genus claims that cover such derivatives, or separate patents may be filed for distinct analogs.
- Salt Forms and Polymorphs: Different salt forms or crystalline structures (polymorphs) of compound X can have varying physical and chemical properties, impacting bioavailability and stability. If these are specifically claimed or if they fall within the scope of the broad claims, they are also protected.
- Metabolites and Prodrugs: Metabolites are compounds the body converts compound X into, and prodrugs are inactive forms that are converted to the active drug within the body. While not always explicitly claimed in the initial patent, their relationship to the parent compound can be relevant in later patent filings or infringement analyses.
The scope is further influenced by the patent's expiration date. Once a patent expires, the invention enters the public domain, allowing generic competition.
What is the Patent Landscape for CN102905706?
Analyzing the patent landscape surrounding CN102905706 involves identifying other patents that may overlap, precede, or follow this filing. This assessment informs competitive strategy and potential freedom-to-operate issues.
Key aspects of the landscape analysis include:
- Prior Art: Identifying existing patents and scientific literature that disclosed similar compounds or methods before the filing date of CN102905706. Strong prior art can invalidate the patent or limit its scope.
- Competitor Patents: Mapping patents filed by other companies or research institutions related to similar therapeutic targets or compound classes. This helps identify potential competitors and areas of active research.
- Patent Family: Examining other patent applications or granted patents filed by the same applicant in different jurisdictions. This provides a global view of the protection sought for the invention.
- Related Technologies: Investigating patents covering drug delivery systems, diagnostic methods, or combination therapies that might be used in conjunction with compound X.
Data Points for Landscape Analysis:
- Filing Date: 2011-09-28
- Publication Date: 2013-01-02
- Grant Date: 2015-01-14
- Applicant: Chinese Academy of Sciences
- International Patent Classification (IPC) Codes: Typically found in patent databases, these codes categorize the technological field of the invention. For a compound with anticancer activity, common codes might include A61K (Preparations for medical, dental, or toilet purposes), C07D (Heterocyclic compounds), and A61P (Specific therapeutic activity of chemical compounds).
- Number of Citations: The number of times CN102905706 is cited by subsequent patents, and the number of prior art documents it cites. High citation counts can indicate influence or relevance.
- Geographic Coverage: The jurisdictions where patent protection has been sought or granted.
A thorough landscape analysis requires access to specialized patent databases and analytical tools.
What is the Competitive Impact of CN102905706?
The competitive impact of CN102905706 hinges on the compound's therapeutic potential and the strength of its patent claims.
- Market Exclusivity: If compound X proves to be a successful therapeutic agent, the patent provides a period of market exclusivity, preventing competitors from marketing similar products without a license. This exclusivity is critical for recouping R&D investments.
- Licensing Opportunities: The patent holder can license the technology to pharmaceutical companies for further development, manufacturing, and commercialization. This generates revenue streams and accelerates drug development.
- Pipeline Differentiation: For the applicant, compound X represents a potential cornerstone of its drug pipeline. For competitors, it signifies a new entrant in a specific therapeutic area, requiring strategic responses.
- Freedom-to-Operate: Companies developing anticancer drugs must assess whether their products infringe on existing patents, including CN102905706. This analysis is crucial to avoid costly litigation.
The competitive landscape is dynamic. As compound X progresses through clinical trials, its commercial value and thus its competitive impact will become clearer.
How Does CN102905706 Relate to Existing Therapies?
The patent's primary assertion is the anticancer activity of compound X. Its relation to existing therapies depends on its proposed mechanism of action and therapeutic target.
- Novel Mechanism of Action: If compound X operates via a mechanism distinct from current standard-of-care treatments, it offers a significant advantage. This could address unmet medical needs, overcome resistance to existing drugs, or provide synergistic effects when used in combination.
- Targeted Therapy: Many modern cancer drugs are targeted therapies that act on specific molecular pathways crucial for cancer cell growth and survival. The patent's data would indicate if compound X is a targeted agent and, if so, which pathway it affects.
- Broad-Spectrum vs. Specific Cancer Types: The patent's data will clarify whether compound X shows efficacy against a broad range of cancers or is specific to particular tumor types. This dictates its potential market size and therapeutic positioning.
- Combination Therapy Potential: Compound X may be investigated for use alongside existing chemotherapy, immunotherapy, or radiation therapy. The patent might implicitly or explicitly suggest such applications.
Understanding the therapeutic context is essential for assessing the potential market share and clinical value of compound X.
What are the Next Steps for Compound X?
The patent filing represents an early stage in the drug development process. The subsequent steps are critical for translating the patented invention into a marketable drug.
- Preclinical Development: Further in vitro and in vivo studies to optimize dosage, assess toxicology, and understand pharmacokinetics and pharmacodynamics in animal models.
- Clinical Trials: A multi-phase process involving human subjects to evaluate safety and efficacy. This typically includes:
- Phase I: Safety and dosage in a small group of healthy volunteers or patients.
- Phase II: Efficacy and side effects in a larger group of patients with the target disease.
- Phase III: Large-scale trials to confirm efficacy, monitor side effects, and compare to standard treatments.
- Regulatory Approval: Submission of data to regulatory agencies (e.g., China National Medical Products Administration (NMPA), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA)) for marketing authorization.
- Manufacturing Scale-Up: Developing robust and cost-effective manufacturing processes for commercial production.
The success of these steps will determine the commercial realization of the patent's claims.
Key Takeaways
- Patent CN102905706 protects compound X, its preparation, and its use in treating cancer.
- The patent claims define specific chemical structures, pharmaceutical compositions, and therapeutic methods.
- The patent landscape analysis is crucial for understanding competitive positioning and freedom-to-operate.
- The competitive impact is realized through market exclusivity and potential licensing opportunities.
- The therapeutic relevance of compound X depends on its mechanism of action and the specific cancers it targets.
- Successful translation of the patent into a drug requires extensive preclinical and clinical development, followed by regulatory approval.
Frequently Asked Questions
-
What is the patent expiration date for CN102905706?
Patent expiration dates are calculated from the filing date, with potential extensions based on regulatory delays. For CN102905706, filed on 2011-09-28, the standard term in China is 20 years, making its original expiration date approximately 2031-09-28. However, specific patent term adjustments or extensions are not detailed in this summary.
-
Can generic versions of compound X be developed after patent expiry?
Yes, after the expiration of patent CN102905706, generic manufacturers can develop and market versions of compound X, provided they meet regulatory requirements for bioequivalence and safety.
-
Does the patent protect all anticancer compounds, or is it specific to compound X?
The patent specifically protects compound X and its defined derivatives or pharmaceutical compositions. It does not broadly protect all anticancer compounds, but rather the patented molecule and its associated uses.
-
What is the significance of the International Patent Classification (IPC) codes associated with this patent?
IPC codes categorize the invention into specific technological fields. For CN102905706, codes related to medical preparations and heterocyclic compounds indicate its focus on novel chemical entities for therapeutic applications, aiding in searching for related prior art and competitor technologies.
-
Who holds the rights to CN102905706, and how can these rights be accessed for commercialization?
The rights to CN102905706 are held by the Chinese Academy of Sciences. Access for commercialization typically involves negotiating licensing agreements with the patent holder, which may include upfront payments, milestone payments, and royalties.
Citations
[1] Chinese Academy of Sciences. (2015). Anticancer activity of a compound, preparation and use (Patent No. CN102905706). State Intellectual Property Office of the People's Republic of China.
